INTRODUCTION
Clonal cell lineage involvement in myelodysplastic syndrome and acute myeloid leukemia (AML) carrying recurrent genetic abnormalities can be successfully investigated by a number of techniques, including cytogenetics, fluorescence in situ hybridization (FISH), FISH combined with immunophenotyping (FICTION), and polymerase chain reaction (PCR) on purified cell populations, which are all able to detect leukemia-specific molecular alterations [1] [2] [3] [4] [5] [6] [7] . Unfortunately, no specific genetic markers are as yet available for a significant proportion of AML. Under these circumstances, cell lineage clonality can be investigated by analysis of X-chromosome inactivation patterns 8 , but this technique has not been applied widely to AML. Thus, no or scarce information is available on cell lineage involvement or cell of origin in most AML, especially those with normal karyotype (AML-NK) 9 , which lack specific clonality markers and account for 40-50% of de-novo adult AML 10 . All genetically poorly defined AML, including AML-NK, are now included into the category of "acute myeloid leukemia not otherwise characterized" of the World Health Organization (WHO) classification 11 . This large, poorly characterized subgroup of AML is currently defined according to criteria of the French-American-British (FAB) classification 12 (with some modification), which is based on morphological/cytochemical features of the leukemic cells and degree of maturation. Given its frequency and extreme heterogeneity, "AML not otherwise characterized" clearly needs to be defined better.
We recently identified mutations of the NPM gene exon-12 as the most common and specific genetic lesion associated with AML-NK 13 , being observed in 50-60% of cases, as confirmed to date in >3,500 AML patients [14] [15] [16] [17] [18] [19] . At the NPM protein C-terminus, these mutations modify critical tryptophan(s) and create a new nuclear export signal (NES) motif, which act together to aberrantly localize NPM leukemic mutants in the cytoplasm 20, 21 .
Hence the term NPMc+ (cytoplasmic-positive) AML 13 . As the NPM mutant protein dislocates the NPM wild-type allele into the cytoplasm 20 and prevents the p19(Arf) tumor suppressor from initiating a p53 response that induces cell cycle arrest 22, 23 , NPM mutations appear critical in NPMc+ AML pathogenesis.
In this study, we tested mutated/cytoplasmic NPM as a clonality marker in a large cohort of NPMc+ AML patients, and used it to assess lineage involvement and cell of origin, and to determine the validity of FAB criteria in defining the WHO category of "acute myeloid leukemia not otherwise characterized" 11 . To address these issues, we screened laser-microdissected cells of different lineages from three NPMc+ AML patients for the presence of NPM exon-12 mutations, and sought cytoplasmic mutated NPM proteins in 161 NPMc+ AML paraffin-embedded bone marrow biopsies using anti-NPM antibodies, including reagents that specifically recognize mutant NPM proteins on Western blotting and immunohistochemistry 20, 24 . Immunohistochemical results were then correlated with FAB criteria adopted in the WHO classification.
We found that clonal NPM mutations affect different cell lineages in about 60% of NPMc+ AML, suggesting that either a common myeloid or an earlier progenitor without the ability to differentiate into lymphoid lineages is involved in NPMc+ AML. These findings also led us to question the FAB criteria that currently define the large WHO category of "acute myeloid leukemia not otherwise characterized" 11 , as they emerged as inapplicable to NPMc+ AML.
MATERIALS AND METHODS

Tumour samples
NPM mutations were investigated in 3 NPMc+ AML-NK where frozen bone marrow biopsies were available for laser-capture microdissection of leukemic cells. Data on NPM exon-12 mutations in the bulk bone marrow population were available from patient 1 (heterozygous mutation B) and patient 3 (heterozygous mutation A) 13 (Table 1) . samples of AML-NK lacking NPM mutations were used 13 . All bone marrow biopsies were fixed in B5 and decalcified in EDTA, as previously described 13 . Immunohistochemical results were correlated with currently used FAB criteria in the WHO classification 11 .
NPM mutation analysis on laser-microdissected cells
Frozen sections (9 µ m-thick) from undecalcified bone marrow biopsies 25 were attached on membrane-slides (P.A.L.M. Microlaser Technologies AG, Hamburg, Germany) and air-dried overnight at room temperature. Antibodies against NPM are not suitable for detecting cytoplasmic NPM in frozen sections 13 . Therefore, for selecting cells to microdissect, glycophorin A ( Figure 1A ) and CD61 ( Figure 1C) 
NPM mutation analysis
Pooled cells in 20 µl volume were incubated with Proteinase K (0.25 µg/µl) for 4 h at 50˚C, followed by 10' at 95˚C for enzyme inactivation. A nested PCR strategy was used to amplify a genomic fragment spanning the NPM exon-12 sequence 13, 20 . PCR products were purified using the QIAQUICK purification kit (QIAGEN) and sequenced directly using primer NPM1-1112R (5'-CCTGGACAACATTTATCAAACACGGTA-3') and NPM-ex12R5'. All sequences were compared with the germline NPM cDNA sequence (GenBank Accession No. NM_002520 version 4).
Antibodies
Nucleophosmin was detected in paraffin sections using the following antibodies:
monoclonal anti-NPM antibodies (clones 322 and 376), recognizing both wild-type and mutant NPM 13, 20, 29 ( Fig. 2A, left) ; polyclonal antibodies (Sil-A and Sil-C) 20, 24 , which detect mutated but not wild-type NPM ( Fig. 2A, left) ; and a monoclonal antibody (clone FC-61991) that recognizes wild-type but not mutated NPM ( Fig. 2A, Dako, Glostrup, Denmark) were also used.
Immunohistochemical studies
Paraffin sections from all bone marrow samples were subjected to antigen retrieval (microwaving in 1 mM EDTA buffer, pH 8.0) 13 and incubated with primary antibodies. The antigen-antibody reaction was revealed using the immuno-alkaline phosphatase (APAAP) technique 13, 30 ; double staining for glycophorin A/NPM was performed using a sequential APAAP/immunoperoxidase procedure 31 . In selected NPMc+ AML cases, double immunofluorescence for myeloperoxidase/NPM was carried out, as previously described 32 .
Lineage involvement criteria
Immunohistological findings were related to morphological features, according to the WHO classification 11 . Involvement of myeloid and monocytic cell lineages was easy to detect since NPMc+ myeloid and monocytic cells usually represented the majority of the leukemic population. The following criteria were used to define involvement of erythroid and megakaryocytic series: erythroid cells were considered as involved when even a few surface glycophorin A-positive cells expressing cytoplasmic NPM and nuclear C23 were detected. Cytoplasmic expression of NPM (not related to the presence of NPM mutations)
is sometimes seen in megakaryocytes in normal and pathological bone marrows.
Therefore, criteria for megaryocyte involvement was represented by >50% megakaryocytes expressing cytoplasmic NPM in presence of nuclear C23. Erythroid and/or megakaryocytic involvement was confirmed by Sil-A and Sil-C antibody detection of mutated NPM when antigens survived fixation/decalcification Figure 1C ). Fibroblasts or vessels were also isolated as negative control from patients 2 and 3 (Table 1) , while no control could be microdissected from patient 1 ( Table 1) .
RESULTS
NPM mutations target different cell lineages in NPMc+ AML
For each lineage, 3-4 independent pools of cells were investigated in the three patients, corresponding to a total of 31 samples; of these, twenty-six (84%) were successfully amplified. Lack of amplification in the remaining 5 samples was probably due to loss of DNA during laser microdissection or to incomplete proteinase K digestion.
Sequencing analysis revealed the presence of heterozygous, clonal NPM exon-12 mutations in all patients (Table 1) . Patient 1 carried a 4-bp insertion (CATG) at position 960_963, corresponding to mutation B 13 , which was detected in each sample amplified (3 myeloid, 3 erythroid, 4 megakaryocyte) ( Table 1 ; Figure 1B ), confirming the results obtained by mutational analysis of the bone marrow bulk population. In patient 2, 6/8 samples amplified (2 myeloid, 2 erythroid and 2 megakaryocyte) displayed a TCTG duplication at position 960_963, corresponding to mutation "A", the most frequent in NPMc+AML 13 . Conversely, only wild-type sequences were detected in the remaining two samples (one myeloid, one erythroid) (Table 1) . However, this patient carried a heterozygous single base-pair deletion (∆T1146) in the untranslated sequences of the same exon, which was also observed in paired DNA from normal fibroblasts and corresponds to a frequent, previously described germline polymorphism 17 . The deletion T1146 co-segregated with the allele lacking the TCTG duplication (data not shown), and could therefore be used as a marker for allelic representation. Indeed, only one allele (i.e., the wild-type) was detected in these two samples, indicating that the absence of NPM exon-12 mutations was due to lack of amplification of the second allele, as occasionally observed in single-cell based approaches. Patient 3, where only cells of megakaryocytic lineage could be analyzed, carried mutation "A", which was detected in all four samples sequenced ( Figure 1C and D, bottom panel). No somatic NPM mutations were found in fibroblasts or endothelial cells microdissected from the same section in two patients (2 and 3, respectively) with available material, excluding contamination from adjacent cells (Table   1 ; Figure 1D , top panel).
Thus, in each patient, the same mutation was found in different cell types of the myeloid lineage, documenting their clonal origin and validating immunohistochemical data of aberrant cytoplasmic NPM expression.
NPMc+ AML cells of different lineages harbour cytoplasmic mutated NPM proteins.
To determine whether cells of different lineages in NPMc+ AML carry NPM mutated proteins, we immunostained for NPM paraffin-embedded biopsies from 161 NPM+ AML patients.
Reactivity with antibodies recognizing both wild-type and mutated NPM proteins
These antibodies reacted strongly with 161/161 biopsies ( As expected, 25 AML-NK samples without NPM mutations (negative control)
showed nucleus-restricted NPM and C23 expression 13 .
Reactivity with specific anti-NPM mutant antibodies
To These findings prove that, in NPMc+ AML, cells of different lineages carry in the cytoplasm both mutated and wild-type NPM proteins.
Cytoplasmic NPM, multilineage involvement and AML classification
ImmunohistoIogical findings were used to assess FAB criteria in the current WHO classification of AML 11 . Table 2 These findings highlight the inadequacy of FAB categories in defining NPMc+ AML.
DISCUSSION
In this study, we found that clonal NPM mutations occur in two or more cell lineages in about 60% of NPMc+ AML, suggesting derivation from either a common myeloid progenitor or an earlier progenitor without the ability to differentiate into lymphoid lineages.
Our findings also demonstrate that FAB criteria are inapplicable to NPMc+ AML, thus questioning current WHO definition criteria for the category of "acute myeloid leukemia not otherwise characterized" 11 .
Mutated NPM is a unique cell lineage clonality marker in AML, which also permits the study of the poorly characterized subgroup of AML-NK. FISH cannot detect NPM mutations and searching for them in microdissected cells is technically demanding. A very promising approach is to search for NPM mutations in AML subpopulations at various differentiation stages after separation by fluorescence-activated cell sorting (FACS).
Because of the lack of fresh leukemic cells for FACS analysis, we used immunohistochemistry on paraffin-embedded samples to study lineage involvement in AML. This technique is simple and cheap, and also has the advantage, compared with FACS studies, of allowing cytoplasmic NPM to be correlated with optimal cytological details. Combining immunohistochemistry with bone marrow biopsy was invaluable, since it served to identify cytoplasmic NPM even in isolated or clusters of erythroid or megakaryocyte cells, to assess dysplastic features, and to define distribution of leukemic infiltrates (e.g. relationship with bone trabeculae or other structures).
The most suitable reagents for labelling routine bone marrow biopsies are antibodies recognizing both wild-type and mutant NPM 13, 29 , since the epitopes recognized by these reagents are strongly resistant to fixatives. These antibodies predict the presence of mutated NPM in cells of different lineages, by detecting aberrant cytoplasmic NPM expression. This finding was corroborated by immunostaining with specific anti-NPM mutant antibodies and by molecular data from laser-microdissected cells from three NPMc+ AMLs, with two patients displaying mutation "A" and one mutation "B". These mutations are predicted to encode for NPM proteins carrying, at their C-terminus, mutated tryptophan(s) and a new NES motif, which are both crucial for nuclear export and aberrant NPM cytoplasmic accumulation in leukemic cells 20 .
To date, information on lineage involvement in AML is scarce and usually limited to small series of patients 1, 2, 4, 6, [38] [39] [40] . In AML with recurrent chromosomal abnormalities, such as t(15;17), t(8;21) or Inv (16), only a single cell lineage appears to be involved [41] [42] [43] [44] .
Multilineage involvement is frequently observed in AML patients carrying the inv(3)(q21q26) 40 . Due to the lack of specific clonality markers, no information on cell lineage is available in AML-NK. Cuneo et al. could not detect any cryptic chromosome aberrations using FISH techniques 9 . In this study, we report a high frequency of involvement of two or more cell lineages in about 60% of NPMc+ AML. Since cytoplasmic/mutated NPM is closely associated with normal karyotype 13 , our findings represent the first demonstration of high frequency of multilineage involvement in a large group of AML-NK.
Notably, all our cases with multilineage involvement were de-novo AML, which concurs with previous observations that cytoplasmic/mutated NPM is very rare in secondary AML 13 . This is a novel finding, since Bernell et al. 45 , using FISH combined with standard morphology (MGG/FISH), have shown multilineage involvement is more frequent in secondary than in de-novo AML. However, our findings are not in conflict with this study, since the 6 de-novo AML they investigated carried cytogenetic abnormalities, which are usually mutually exclusive with cytoplasmic/mutated NPM. Interestingly, multilineage involvement has also been detected in de-novo AML where the NPM gene fuses with the MLF1 gene as result of the t(3:5) translocation 46 . In our NPMc+ AML cases, there was no correlation between types of NPM mutations and type/frequency of lineage involvement, consistent with the observation that, despite molecular heterogeneity, all NPM mutants share the same alterations at their C-terminus. These molecular alterations are responsible for the cytoplasmic accumulation of NPM mutants, which may represent an important event in promoting the leukemic process. Multilineage involvement also appears to be an intrinsic feature of NPMc+ AML, independent of the presence of additional genetic alterations, such as FLT3-ITD.
Although 40% of the NPMc+ AML cases in this study showed no immunohistochemical evidence of multilineage involvement, lack of detection may be due to technical limitations. The number of NPMc+ erythroid and megakaryocytic cells might be too low to be detected and, as multilineage involvement is sometimes found in isolated areas of a tissue section but not in others, timing and sample size could underlie lack of detection. Thus, the fraction of NPMc+ AML cases with multilineage involvement may be even higher than the 60% demonstrated in this study. Since patients in our series were heterogeneous in terms of age and treatment, the pattern of lineage involvement could not be correlated with clinical outcome. A large cohort of uniformly treated patients enrolled in multicentre clinical trials is required to investigate this issue.
The cell of origin of NPMc+ AML remains unknown. Our findings that mutated NPM is expressed in myeloid, monocytic, erythroid and megakaryocytic cells but not in lymphoid elements suggest derivation of NPMc+ AML from either a common myeloid precursor or an earlier progenitor without the ability to differentiate into lymphoid lineages. This view is in keeping with the distinctive gene expression signature of NPMc+ AML, which is characterized by up-regulation of genes involved in stem cell maintenance, e.g. most HOX genes 18, 47 . Negativity for CD34, a consistent feature of NPMc+ AML 13 , might reflect CD34 down-regulation due to leukemic transformation or derivation from the few lineage-markernegative CD34-negative/CD38-negative hematopoietic stem cells in the bone marrow 48 .
The nature of the NPMc+ AML cell of origin will need to be addressed in depth by These results impact profoundly upon the current WHO classification of AML which incorporates morphologic, immunophenotypic, genetic, and clinical features "in an attempt to define entities that are biologically homogeneous and that have clinical relevance" 11 .
The WHO classification of AML encompasses four major categories: 1) AML with recurrent genetic abnormalities, usually occurring in younger individuals and associated with relatively good response to therapy and outcome; 2) AML with multilineage dysplasia, more frequent in older patients, often carrying unfavourable cytogenetics; 3) therapyrelated AML, a poor prognostic subgroup; and 4) AML "not otherwise characterized" encompassing cases that do not fulfil criteria for inclusion in the other groups.
Unfortunately, 60-70% of all de-novo AML fall within the last category, which, as it includes AML with normal karyotype (i.e. 40-50% of all de-novo adult AML), embraces a greater percentage of AML cases than the sum total of the other three categories. Thus, "AML not otherwise characterized" clearly needs to be better defined. Undoubtedly, future classification schemes of AML, especially the category with normal karyotype, will have to take into consideration a number of genetic and molecular criteria, including newly discovered AML-associated genetic lesions and distinctive molecular signatures highlighted by gene expression profiling 51, 52 . 
